These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 1079276)

  • 1. [Delayed hypersensitivity and its clinical application--malignant melanoma].
    Ishihara K
    Nihon Hifuka Gakkai Zasshi; 1975 Mar; 85(3):130-1. PubMed ID: 1079276
    [No Abstract]   [Full Text] [Related]  

  • 2. Delayed cutaneous sensitivity reactions to extracts of autologous malignant melanoma: a second look.
    Bluming AZ; Vogel CL; Ziegler JL; Kiryabwire JW
    J Natl Cancer Inst; 1972 Jan; 48(1):17-24. PubMed ID: 4652371
    [No Abstract]   [Full Text] [Related]  

  • 3. [Immunology of malignant melanoma].
    Misgeld V
    Hautarzt; 1973 Dec; 24(12):511-9. PubMed ID: 4599321
    [No Abstract]   [Full Text] [Related]  

  • 4. [Correlation of the level of humoral cytotoxins and delayed hypersensitivity skin reactions with survival of patients with melanoma of the skin].
    Korosteleva TA; Vagner RI; Veresova OV; Potapenkova LS
    Vopr Onkol; 1983; 29(4):38-40. PubMed ID: 6858049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cutaneous, cellular immunity in malignant melanoma].
    Kehrer HC
    Wien Klin Wochenschr; 1991; 103(13):396-7. PubMed ID: 1897233
    [No Abstract]   [Full Text] [Related]  

  • 6. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response.
    Barth A; Hoon DS; Foshag LJ; Nizze JA; Famatiga E; Okun E; Morton DL
    Cancer Res; 1994 Jul; 54(13):3342-5. PubMed ID: 8012946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Skin reactions of delayed hypersensitivity in melanoblastoma].
    Ryzhkov VI; Potapenkova LS; Korosteleva TA; Khachaturian LM
    Vopr Onkol; 1979; 25(4):3-6. PubMed ID: 433214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [State of the stroma in melanoma in patients with different delayed hypersensitivity reaction to neoplasm antigen].
    Lavnikova GA; Voronina EA; Babakova SV
    Vopr Onkol; 1978; 24(11):24-30. PubMed ID: 741696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Delayed hypersensitivity reaction in malignant melanoma].
    Gorodilova VV; Saraeva ZM; Slesareva RI; Monzul' GD
    Vopr Onkol; 1973; 19(3):23-7. PubMed ID: 4762691
    [No Abstract]   [Full Text] [Related]  

  • 10. Cutaneous delayed hypersensitivity reactions to soluble melanoma antigen in patients with ocular malignant melanoma.
    Char DH; Hollinshead A; Cogan DG; Ballintine EJ; Hogan MJ; Herberman RB
    N Engl J Med; 1974 Aug; 291(6):274-7. PubMed ID: 4407111
    [No Abstract]   [Full Text] [Related]  

  • 11. Delayed hypersensitivity reaction at metastatic tumor sites.
    Gerner RE; Moore GE; Tabron DS
    Rocky Mt Med J; 1975 Jan; 72(1):17-20. PubMed ID: 1053840
    [No Abstract]   [Full Text] [Related]  

  • 12. Some aspects of cell-mediated hypersensitivity in patients with melanoma.
    Moszkowska G; Jassem J; Kondrat W; Kopacz A; Goszczyńska E
    Arch Immunol Ther Exp (Warsz); 1980; 28(4):655-60. PubMed ID: 6970028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.
    Waanders GA; Rimoldi D; Liénard D; Carrel S; Lejeune F; Dietrich PY; Cerottini JC; Romero P
    Clin Cancer Res; 1997 May; 3(5):685-96. PubMed ID: 9815737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative evaluation of lymphocyte subpopulations, delayed cutaneous hypersensitivity reactions and autoantibody formation in cancer patients.
    Pichler WJ; Stingl G; Wagner G; Micksche M; Neumann H; Knapp W
    Osterr Z Onkol; 1977 Nov; 4(5-6):110-7. PubMed ID: 202907
    [No Abstract]   [Full Text] [Related]  

  • 15. [Cellular immunity in patients with melanoma].
    Gorodinova VV; Kholenshed A; Babakova SV
    Vopr Onkol; 1976; 22(12):3-5. PubMed ID: 1020253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production of melanoma-associated antigen(s) by a defined malignant melanoma cell strain grown in chemically defined medium.
    Chee DO; Boddie AW; Roth JA; Holmes EC; Morton DL
    Cancer Res; 1976 Apr; 36(4):1503-9. PubMed ID: 1260767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunologic evaluation of the cancer patient during immunotherapy.
    Boehm OR; Boehm BJ; Jewell WR; Humphrey LJ
    Natl Cancer Inst Monogr; 1972 Dec; 35():403-8. PubMed ID: 4633407
    [No Abstract]   [Full Text] [Related]  

  • 18. [Changes in certain immunological parameters in patients with malignant skin melanoma].
    Lukács L; Bárdosi L; Somos Z; Kocsis B
    Orv Hetil; 1985 Apr; 126(14):819-26. PubMed ID: 3873050
    [No Abstract]   [Full Text] [Related]  

  • 19. Abrogation of anterior-chamber-induced suppression of delayed-type hypersensitivity responses by monoclonal anti-I-J antibodies.
    Niederkorn JY; Waltenbaugh C; Streilein JW
    Transplantation; 1984 Jun; 37(6):623-5. PubMed ID: 6233772
    [No Abstract]   [Full Text] [Related]  

  • 20. [Study on cellular immunity and immunotherapy of malignant melanoma (author's transl)].
    Ishihara K
    Nihon Hifuka Gakkai Zasshi; 1975 Oct; 85(12):696-8. PubMed ID: 1238716
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.